Annual Report

Fiscal Year 2018-2019

July 1, 2019
Mission

Created by the Louisiana Legislature in 1888, the mission of the Louisiana Board of Pharmacy remains unchanged over a century later: to regulate the practice of pharmacy in such a manner as to protect the public health, safety, and welfare of the citizens of Louisiana. Toward that goal, the Louisiana Pharmacy Practice Act specifically authorizes the Board to restrict the practice of pharmacy to qualified persons, as well as to control and regulate all persons and sites that sell prescription drugs or devices or provide pharmacy care services to consumers in this state.

Licensure

In order to facilitate the restriction of practice to qualified persons, the Board has established educational, experiential, and examination requirements for pharmacist licensure. As authorized by the legislature, the Board has contracted its high-stakes examination procedures with professional testing services.

A. Examinations for Pharmacists

The North American Pharmacist Licensure Examination (NAPLEX) and the Multistate Pharmacy Jurisprudence Examination (MPJE) are administered by the National Association of Boards of Pharmacy (NABP). These computer adaptive tests are administered in continuous window opportunities at multiple sites throughout the state. A minimum scaled score of 75 is required on each test to qualify for pharmacist licensure; the maximum scaled score is 150 for the NAPLEX and 100 for the MPJE. NABP publishes summary data for the examinations on a trimester basis. The results for all Louisiana-based NAPLEX and MPJE candidates in Calendar Year 2018 are summarized here:

### NAPLEX

<table>
<thead>
<tr>
<th></th>
<th>Jan – Apr</th>
<th>May – Aug</th>
<th>Sept – Dec</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of Louisiana Candidates</td>
<td>17</td>
<td>215</td>
<td>50</td>
</tr>
<tr>
<td>State Mean Scaled Score</td>
<td>72.88</td>
<td>93.10</td>
<td>76.24</td>
</tr>
<tr>
<td>Louisiana Pass Rate</td>
<td>35.29%</td>
<td>86.98%</td>
<td>50%</td>
</tr>
<tr>
<td>No. of National Candidates</td>
<td>1,349</td>
<td>13,152</td>
<td>3,582</td>
</tr>
<tr>
<td>National Mean Scaled Score</td>
<td>77.61</td>
<td>96.25</td>
<td>82</td>
</tr>
<tr>
<td>National Pass Rate</td>
<td>56.56%</td>
<td>89.57%</td>
<td>69.24%</td>
</tr>
</tbody>
</table>

### MPJE

<table>
<thead>
<tr>
<th></th>
<th>Jan – Apr</th>
<th>May – Aug</th>
<th>Sept – Dec</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of Louisiana Candidates</td>
<td>111</td>
<td>370</td>
<td>211</td>
</tr>
<tr>
<td>State Mean Scaled Score</td>
<td>78</td>
<td>77.47</td>
<td>76.64</td>
</tr>
<tr>
<td>Louisiana Pass Rate</td>
<td>82.79%</td>
<td>78.82%</td>
<td>69.19%</td>
</tr>
<tr>
<td>No. of National Candidates</td>
<td>5,845</td>
<td>18,851</td>
<td>9,201</td>
</tr>
<tr>
<td>National Mean Scaled Score</td>
<td>77.49</td>
<td>78.21</td>
<td>76.94</td>
</tr>
<tr>
<td>National Pass Rate</td>
<td>76.46%</td>
<td>83.07%</td>
<td>72.86%</td>
</tr>
</tbody>
</table>
B. Examinations for Technicians
The Board has approved two pharmacy technician certification examinations – the Pharmacy Technician Certification Examination (PTCE) administered by the Pharmacy Technician Certification Board and the Examination for Certified Pharmacy Technicians (ExCPT) administered by National Healthcareer Association (NHA). Both examinations are computer adaptive tests which are administered in continuous window opportunities at multiple sites throughout the state. The results for all Louisiana-based PTCE and ExCPT candidates for Calendar Year 2018 are summarized here:

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of Louisiana Candidates</td>
<td>657</td>
<td>572</td>
<td>57</td>
<td>66</td>
</tr>
<tr>
<td>Louisiana Pass Rate</td>
<td>40.9%</td>
<td>44.1%</td>
<td>46.2%</td>
<td>63.6%</td>
</tr>
<tr>
<td>No. of National Candidates</td>
<td>27,331</td>
<td>21,512</td>
<td></td>
<td></td>
</tr>
<tr>
<td>National Pass Rate</td>
<td>57%</td>
<td>58%</td>
<td>64%</td>
<td>70%</td>
</tr>
</tbody>
</table>

C. Census Data
At the close of the fiscal year on June 30, 2019, a review of our records yielded the following census information:

- Pharmacy Program
  1. Pharmacists
     > Number of active licenses 9,255 9,009 8,577
     > Number of licensees within the state 5,795 5,690 5,588
  2. Pharmacy Interns
     > Number of active registrations 1,094 1,070 1,094
  3. Pharmacy technicians
     > Number of active certificates 6,601 6,586 6,561
  4. Pharmacy technician candidates
     > Number of active registrations 1,595 2,000 2,052
  5. Pharmacies
     > Number of active permits 2,033 1,988 1,983
       - Community – Independent 605 590 583
       - Community – Chain 596 630 651
       - Hospital 172 175 175
       - Institutional 22 22 23
       - Marijuana 8 0 0
       - Nuclear 13 13 14
       - Charitable 9 10 11
       - Penal 4 3 2
       - Remote processor 2 1 0
       - Nonresident 572 544 524
  6. Equipment Permits
     > Emergency drug kit (EDK) 380 446 411
     > Automated medication systems (AMS) 461 870 439
     > Durable medical equipment (DME) 640 642 637
7. Special Activity Credentials
   > CDTM Registration 78  69  66
   > Med. Administration Registration 3,161 3,073 2,820
   > Special Work Permits 41  45  48
   > Marijuana Pharmacy Designations 127  71  0
   > PMP Access Registrations 19,686 15,835 (new)

   Subtotal of Credentials in Pharmacy Program 45,174 41,770 24,688

   2018  2018  2017

   • CDS Program
     1. Automated Medication System (AMS) 42  37  28
     2. Advanced Practice RN (APRN) 3,435 2,980 2,343
     3. Dentist 2,224 2,174 1.929
     4. Drug Detection / Canine 6  8  8
     5. Distributor 285 290 284
     6. Podiatrist 163 158 136
     7. Veterinarian 1,216 1,188 1,007
     8. Animal Euthanasia Technician 28  29  25
     9. Hospital 302 306 283
    10. Laboratory 12  12  11
    11. Physicians & Interns/Residents 14,196 13,144 11,575
    12. Manufacturer 47  45  38
    13. Medical Psychologist 91  91  84
    14. Optometrist 360 349 297
    15. Pharmacies 1,303 1,335 1,359
    16. Physician Assistant 928 783 667
    17. Registered Outsourcing Facility 19  19  13
    18. Researcher 106 104 100
    19. Substance Abuse Clinic 6  6  6

   Subtotal of Credentials in CDS Program 24,769 23,058 20,193

Total Active Credentials under Management 69,943 64,828 44,881

D. New Credentials
During the past fiscal year, the Board issued 5,864 new credentials in the Pharmacy Program and 2,929 new credentials in the CDS Program. Of note within the Pharmacy Program, we issued 523 new pharmacist licenses, 527 new pharmacy technician certificates, and 1,034 new pharmacy technician candidate registrations during the past fiscal year. Of note within the CDS Program, we issued new CDS licenses to 1,720 physicians, interns and residents, as well as 577 advanced practice registered nurses, and 163 dentists.

E. License Transfer (Reciprocity)
Persons already licensed as a pharmacist by any other state who wish to obtain a license in Louisiana must successfully complete the MPJE as well as the application and criminal background check. Of the 523 new pharmacist licenses issued this past fiscal year, 295 were issued subsequent to completion of the reciprocity process.
Compliance

A. Enforcement

In order to control and regulate the practice of pharmacy in Louisiana, the Board employs five pharmacist compliance officers to perform routine inspections and special investigations throughout the year in all places under the Board’s jurisdiction. In addition to pharmacies, the compliance officers also inspect healthcare facilities to monitor compliance with controlled substance requirements. The compliance officers visited 1,426 pharmacies and other facilities during the year to perform routine inspections, site visits for permit changes and other calls for assistance. The compliance and administrative officers began the fiscal year with 180 cases from the previous fiscal year, received 433 new cases, and closed 434 cases, leaving 179 cases for the next fiscal year. Of the 434 cases closed during the fiscal year: 5 of the original complaints were withdrawn, 11 resulted from termination of previously imposed probationary periods, 88 were determined to be without violation, 26 cases were referred to other agencies, 122 resulted in field/administrative corrections, 19 resulted in administrative sanctions, and 163 cases were referred to the Board’s committees. The committees took no action in 12 of their cases, issued approvals for 30 non-disciplinary petitions, and recommended voluntary consent agreements for 121 cases. Of that number, all but five accepted the proposed discipline; those five respondents were referred for formal administrative hearings. The decisions from the formal hearings resulted in one denial of reinstatement, two suspensions, and two revocations.

Compliance officers coordinate other investigative activities with a wide range of agencies, including local police departments, parish sheriff departments, other state regulatory and law enforcement agencies, and federal agencies such as the Drug Enforcement Administration, the Food and Drug Administration, and the Consumer Product Safety Commission. Though the compliance officers utilize the educational approach as the fundamental mechanism to achieve compliance, certain circumstances warrant formal board action.

B. Adjudications

During the past fiscal year, the Board conducted two administrative hearings and levied formal disciplinary action against several credentials. A summary of that activity is presented here:

<table>
<thead>
<tr>
<th>CDS</th>
<th>Pharmacist</th>
<th>Intern</th>
<th>Technician</th>
<th>Candidate</th>
<th>Permit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Denial / Refusal</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Reinstatement</td>
<td>6</td>
<td>0</td>
<td>8</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Change Previous Orders</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Assessment</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>15</td>
</tr>
<tr>
<td>Letter of Warning</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Letter of Reprimand</td>
<td>12</td>
<td>0</td>
<td>12</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Voluntary Surrender</td>
<td>7</td>
<td>0</td>
<td>3</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Probation</td>
<td>14</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Suspension</td>
<td>4</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Revocation</td>
<td>0</td>
<td>0</td>
<td>5</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Other Decisions</td>
<td>20</td>
<td>0</td>
<td>2</td>
<td>1</td>
<td>7</td>
</tr>
</tbody>
</table>
C. Practitioner Recovery Program
The Board established its program in 1988 to assist practitioners obtain treatment for their impairment, maintain their recovery, and assist their re-entry into professional practice. As of July 1, 2019 there were 42 pharmacists, one pharmacy intern, and seven pharmacy technicians actively engaged in the recovery program. They surrendered their credentials while in treatment; following treatment and upon favorable recommendation by board-certified addiction medicine specialists, they applied for the reinstatement of their credentials. The Board reinstated their credentials on probation, and the licensees practice under various restrictions designed to monitor their re-entry to professional practice. In addition, the credentials for 39 pharmacists, two interns, 17 technicians, and four technician candidates were still on active suspension for impairment reasons.

Board Activity

A. Regulatory
The Board’s Regulation Revision Committee is tasked with the continuous review of the Board’s rules and their recommendation for revision as appropriate. The Board initiated and completed two regulatory projects during the fiscal year.

- Louisiana Prescription Drug Uniform Prior Authorization Form, amending LAC 46:LIII.1129 and 1130, in collaboration with the La. State Board of Medical Examiners, as directed by Act 423 of the 2018 Legislature; and
- Naloxone as Drug of Concern, amending LAC 46:LIII.2901, as directed by Act 146 of the 2018 Legislature.

As directed by other legislative acts and by the Board’s own initiative, the Board initiated 17 additional regulatory projects; these are pending review by the Occupational Licensing Review Commission for approval to initiate the formal promulgation process.

B. Legislative
During the 2019 regular session, the Board sponsored three bills, all of which were successful.

- Act 80 amended the prescription monitoring program law to enable the sharing of prescription monitoring information with federal agencies and jurisdictions.
- Act 219 amended the licensing section of the controlled dangerous substance law to authorize the Board to require criminal history record checks for certain applicants for the state controlled dangerous substance license.
- Act 354 amended the state’s list of controlled dangerous substances to harmonize the state list with recent federal scheduling actions.

C. Prescription Monitoring Program
Finally, the Board continued its operation of Louisiana’s Prescription Monitoring Program (PMP). The vendor contract to operate the program is held by Appriss, Inc., based in Louisville, KY. As reported previously, Appriss acquired the previous vendor (Optimum Technology) in 2016 and transitioned the program to its operating platform, Aware Rx. The number of prescribers and dispensers authorized to access the program’s database continues to increase, as has the average number of queries per
day. Since the program is required to file an annual report to the legislature, we have appended that report to this one to facilitate its separation.

**Board Office**

The Board currently employs 22 people on a full-time basis in a variety of professional, technical, and clerical roles; the Board also supports the local Cooperative Office Education (COE) program in Baton Rouge area high schools by hiring high school senior students on a temporary basis. The physical and mailing address of the board office is:

- Louisiana Board of Pharmacy
- 3388 Brentwood Drive
- Baton Rouge, LA 70809-1700
- Telephone (225) 925-6496

The board’s website address is [www.pharmacy.la.gov](http://www.pharmacy.la.gov) and general email is received at info@pharmacy.la.gov.

**Conclusion**

The board has had an active year on several fronts, and all of these activities have contributed to the overall mission of the board. The officers and members of the board, as well as the entire office staff, are committed to achieving our goal of protecting the public’s health, safety and welfare through appropriate regulation of the practice of pharmacy in this state. We understand that public service is a privilege, and we endeavor to render that service honorably.

Respectfully submitted,
Malcolm J Broussard
Executive Director
Prescription Monitoring Program
Annual Report

Fiscal Year 2018-2019

July 1, 2019
Introduction

The Louisiana Prescription Monitoring Program (PMP) is an electronic database used to collect and monitor prescription data for all Schedule II, III, IV, and V controlled substances, as well as certain drugs of concern, dispensed by a pharmacy in Louisiana or to a Louisiana resident from a pharmacy located in another state. The PMP also provides a venue for monitoring patient prescription history for practitioners.

Act 676 of the 2006 Louisiana Legislature authorized the development, implementation, operation, and evaluation of an electronic system for the monitoring of controlled substances and other drugs of concern that are dispensed within the state or to state residents by pharmacies located in other states. The goal of the program is to improve the state’s ability to identify and inhibit the diversion of controlled substances and drugs of concern in an efficient and cost-effective manner and in a manner that shall not impede the appropriate utilization of these drugs for legitimate medical purposes.

The PMP was implemented in August 2008. Pharmacies and dispensing prescribers were instructed how and when to transmit their dispensing transactions to the program vendor for assimilation into the PMP database. Prescribers, dispensers, and other persons authorized to access PMP information were instructed how to secure their access privileges. The web portal to the PMP database was opened to queries on January 1, 2009, and the program remains fully operational.

Advisory Council

The enabling legislation created the PMP Advisory Council to assist the Board in the development and operation of the program. The council consists of the following members, each of whom may appoint a designee:

1. The president of the Louisiana State Board of Medical Examiners;
2. The president of the Louisiana State Board of Dentistry;
3. The president of the Louisiana State Board of Nursing;
4. The president of the Louisiana State Board of Optometry Examiners;
5. The president of the Louisiana Academy of Physician Assistants;
6. The president of the Louisiana Board of Pharmacy;
7. The superintendent of the Louisiana State Police;
8. The administrator of the United States Drug Enforcement Administration;
9. The speaker of the Louisiana House of Representatives;
10. The president of the Louisiana Senate;
11. The chairman of the House Committee on Health and Welfare;
12. The chairman of the Senate Committee on Health and Welfare;
13. The secretary of the Department of Health;
14. The president of the Louisiana State Medical Society;
15. The president of the Louisiana Dental Association;
16. The president of the Louisiana Association of Nurse Practitioners;
17. The president of the Optometry Association of Louisiana;
18. The president of the Louisiana Pharmacists Association;
19. The president of the Louisiana Independent Pharmacies Association;
20. The president of the National Association of Chain Drug Stores;
21. The president of the Louisiana Sheriffs’ Association;
22. The president of the Louisiana District Attorneys Association;
23. The president of the Pharmaceutical Research and Manufacturers of America; and
24. The president of the Louisiana Academy of Medical Psychologists.
During Fiscal Year 2018-2019, the council convened all four of their regularly-scheduled quarterly meetings. Representatives from six of the 24 organizations attended 100% of the meetings; ten entities attended 75%; two attended 50%; two attended 25%, and four entities had no representation at any of the meetings. During each of the meetings, program staff presented data concerning the number of prescription transactions reported to the program database as well as the number of queries to the database by prescribers, dispensers, law enforcement, and regulatory agencies. The staff also reported on the addition of new states available through the PMP InterConnect interstate network, as well as the increased utilization by the private sector of the PMP Gateway service, which integrates the PMP access portal into existing practice information systems in a variety of settings, including hospitals, clinics, practitioner offices, and pharmacies. The council reviewed new legislation adopted during the 2018 legislative session, and staff provided updates on the operational implementation of the legislative mandates.

**Vendor Contract**

With the 2013 contract expiring at the end of 2018, the Board solicited public bids for an expanded list of improvements and technical specifications. The La. Office of State Procurement awarded the new contract in January 2019 to Appriss, which was the sole bidder.

**Program Highlights**

- **August 1, 2018** – established access for an epidemiologist with the La. Dept. of Health for public health surveillance purposes, as authorized by 232 of the 2018 Legislature.
- **December 21, 2018** – Louisiana Office of State Procurement awarded the PMP vendor contract to Appriss, Inc. with an effective date of January 1, 2019.
- **April 3, 2019** – through participation with the PMP InterConnect™ sponsored by the National Association of Boards of Pharmacy, achieved connection with the United States Military Health System and 26 states, including Alabama, Alaska, Arizona, Arkansas, Connecticut, Delaware, Florida, Georgia, Idaho, Kansas, Massachusetts, Minnesota, Mississippi, Montana, Nevada, New Mexico, North Carolina, North Dakota, Oklahoma, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Virginia, and West Virginia.
- **May 6, 2019** – first distribution of Prescriber Report Cards. The Prescriber Report Card is intended to give prescribers insight into their opioid prescribing patterns. Reports are provided quarterly to all registered PMP prescriber users with an active account and a defined role and specialty who have written at least one opioid prescription during the prior six-month period.

**Louisiana PMP Statewide Integration Project**

On January 1, 2019, the Board partnered with the Louisiana Dept. of Health’s Office of Public Health, Bureau of Community Preparedness (LDH-OPH-BCP) and Appriss Health to provide a statewide PMP integration option to all healthcare providers in Louisiana utilizing a service called PMP Gateway®. Gateway offers healthcare providers an option to integrate PMP data within the provider’s electronic health record (EHR) or pharmacy information system to provide a streamlined clinical workflow for providers. The integration eliminates the need for providers to log in separately to the PMP web portal; instead, the EHR automatically initiates a patient query and returns the patient’s PMP information directly within the provider’s EHR or pharmacy information system.

Included as part of the integration, users now have access to an advanced analytics and patient
support tool called NarxCare®. In addition to the existing Louisiana PMP functionality, NarxCare aggregates and analyzes prescription information from pharmacies and presents visual interactive information, as well as advanced analytic insights, machine learning risk scores and more to help prescribers and pharmacists provide better patient safety and outcomes for every patient. NarxCare also provides tools and resources that support patients’ needs and assists a healthcare provider to connect their patient to treatment when appropriate. This statewide initiative is funded by a Centers for Disease Control and Prevention (CDC) grant awarded to LDH-OPH-BCP and covers the costs of the licensing fees associated with the integration and NarxCare service.

As of June 30, 2019, the Louisiana PMP was interoperable with 80 licensees (EHR and pharmacy information systems) across the state. There were an additional 179 licensee applicants (EHRs and pharmacy information systems) which had applied for integration and were in process to complete the necessary requirements to obtain access. It is important to note that several licensees have numerous facilities across the state. Ochsner Health System, for example, is one licensee with multiple facilities across the state from New Orleans to Shreveport. Other such licensees include Franciscan Missionaries of Our Lady Health System, Lafayette General Health System, Wal-Mart Pharmacies, and Kroger Pharmacies.

Program Metrics

The data on the following pages provide summary data for the operational aspects of the program for Calendar Year 2018. The first graphic presents information about the use of the information by the authorized users as identified in the governing legislation. Data for the different categories of prescribers are presented, including the number of prescribers authorized to obtain PMP access privileges, the number with active access privileges and the number of queries to the PMP database by those prescribers. Other authorized users include law enforcement and regulatory agencies; information concerning the number of queries originating from those entities is also presented.

The second graphic presents information concerning the numbers of controlled substance prescriptions dispense in the state, including summary data for different types of drugs like opioids and benzodiazepines. Just over 11 million prescriptions were dispensed in the state during Calendar Year 2018, with an average of 2.424 prescriptions per Louisiana resident.

Outlook for Next Fiscal Year

The program is implementing several new features this year, including monitoring for mandatory use compliance as well as the initiation of clinical alerts.

- The controlled substance law contains some mandatory use provisions for certain prescribers in certain situations, and there are some exceptions to those requirements. The monitor can alert staff when prescribers appear to deviate from the mandatory use requirements. Staff will relay the information to the prescriber’s licensing authority which can then determine whether an exception applies or compliance was not achieved.

- The program will offer prescribers multiple types of clinical alerts. These electronic alerts are delivered directly to a prescriber’s dashboard and his email if desired to alert the prescriber that patient has
  - Exceeded a set prescriber/dispenser threshold;
  - Exceeded a daily active MME threshold;
  - Exceeded a daily active MME threshold for methadone;
  - Exceeded a days count threshold for opioid prescriptions; or
  - Been prescribed opioids and benzodiazepines concurrently.
## Authorized User Statistics for Calendar Year 2018

<table>
<thead>
<tr>
<th>Healthcare Provider Roles</th>
<th>Number of Providers Eligible for PMP Access (as of 12/31/2018)</th>
<th>Number of Providers with Active PMP Access Privileges (as of 12/31/2018)</th>
<th>Number of PMP Requests through AWARx™ (as of 12/31/2018)</th>
<th>Number of PMP Requests through GATEWAY™ (as of 12/31/2018)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician (MD, DO)</td>
<td>13,000</td>
<td>8,605</td>
<td>1,393,029</td>
<td>3,543,306</td>
</tr>
<tr>
<td>Nurse Practitioner (APRN)</td>
<td>3,226</td>
<td>2,473</td>
<td>300,383</td>
<td>109,849</td>
</tr>
<tr>
<td>Dentist (DDS)</td>
<td>2,225</td>
<td>1,509</td>
<td>21,658</td>
<td>0</td>
</tr>
<tr>
<td>Physician Assistant (PA)</td>
<td>880</td>
<td>624</td>
<td>65,442</td>
<td>10,435</td>
</tr>
<tr>
<td>Optometrist (OD)</td>
<td>360</td>
<td>148</td>
<td>35</td>
<td>0</td>
</tr>
<tr>
<td>Podiatrist (DPM)</td>
<td>161</td>
<td>109</td>
<td>879</td>
<td>0</td>
</tr>
<tr>
<td>Medical Psychologist (MP)</td>
<td>89</td>
<td>83</td>
<td>19,786</td>
<td>0</td>
</tr>
<tr>
<td>Medical Intern/Resident</td>
<td>1,076</td>
<td>937</td>
<td>3,354</td>
<td>0</td>
</tr>
<tr>
<td>Prescriber’s Delegate</td>
<td>NA</td>
<td>2,127</td>
<td>793,101</td>
<td>NA</td>
</tr>
<tr>
<td>Pharmacist (PST)</td>
<td>9,069</td>
<td>4,156</td>
<td>1,289,904</td>
<td>720,124</td>
</tr>
<tr>
<td>Pharmacist’s Delegate</td>
<td>NA</td>
<td>812</td>
<td>140,533</td>
<td>NA</td>
</tr>
<tr>
<td><strong>Totals</strong></td>
<td><strong>30,086</strong></td>
<td><strong>21,583</strong></td>
<td><strong>4,028,104</strong></td>
<td><strong>4,383,714</strong></td>
</tr>
</tbody>
</table>

### Law Enforcement, Prosecutorial Officials, & Specialty Courts

<table>
<thead>
<tr>
<th>Role</th>
<th>Request Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEA (patient requests)</td>
<td>521</td>
</tr>
<tr>
<td>Specialty Courts</td>
<td>102</td>
</tr>
<tr>
<td>FBI</td>
<td>335</td>
</tr>
<tr>
<td>Homeland Security</td>
<td>3</td>
</tr>
<tr>
<td>Local Law Enforcement</td>
<td>366</td>
</tr>
<tr>
<td>HHS - OIG</td>
<td>12</td>
</tr>
<tr>
<td>State Attorney General</td>
<td>1</td>
</tr>
<tr>
<td>State Police</td>
<td>40</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>1380</strong></td>
</tr>
</tbody>
</table>

### Regulatory Agencies

<table>
<thead>
<tr>
<th>Agency</th>
<th>Request Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>LA State Board of Medical Examiners</td>
<td>1,149</td>
</tr>
<tr>
<td>LA State Board of Dentistry</td>
<td>38</td>
</tr>
<tr>
<td>LA State Board of Nursing</td>
<td>918</td>
</tr>
<tr>
<td>LA State Board of Pharmacy</td>
<td>1,744</td>
</tr>
<tr>
<td>DEA (licensee requests)</td>
<td>808</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>4,657</strong></td>
</tr>
</tbody>
</table>

### Other Roles

<table>
<thead>
<tr>
<th>Role</th>
<th>Request Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical Examiner / Coroner</td>
<td>262</td>
</tr>
<tr>
<td>Louisiana Medicaid</td>
<td>726</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>988</strong></td>
</tr>
</tbody>
</table>
DISPENSATION DASHBOARD
A high level overview of reported dispensation activity.

State Rx per Capita
2.424

Prescriptions
11,307,069

YoY Prescriptions (#)

Schedule 2 2018 5,139,558
Schedule 3 2018 725,533
Schedule 4 2018 4,579,843
Schedule 5 2018 539,681
Unscheduled 2018 321,288
Unspecified 2018 1,166

YoY Prescriptions (#) by Drug Schedule

Opioid 2018 4,786,754
Benzo 2018 2,498,343
Anxiolytic, Hypnotic, Sed. 2018 998,486
Other 2018 3,023,486

YoY Prescriptions (#) by Drug Classes

Prescriptions >= 90 MME vs. All

GTE 90 2.9%
LT 90 97.1%

Rx by Patient Demographic Environment

RURAL 19%
SUPER RURAL 4%
URBAN 77%

New vs. Refill Prescriptions

Refill 20.3%
New 79.7%

Opioids vs. Non Opioids (%)

Non-Opioid 58%
Opioid 42%
Conclusion

The program has completed approximately ten years of operation. Based on feedback from authorized users, it appears to represent an efficient and cost-effective use of resources. Data from the program suggests we have made some progress in the reduction of diversion of controlled substances. Our interstate collaborations have yielded high marks for our program design and operation. We look forward to fully developing the potential of our program to identify and inhibit the diversion of controlled substances in Louisiana.

We appreciate the contributions from and collaboration with our partners on the Prescription Monitoring Program Advisory Council. We also acknowledge the contributions from our administrative coordinators, Ms. Danielle Hartzog and Ms. Nerissa Montgomery, and the program manager, Mr. Joseph Fontenot, for their assistance with the development of this report and administrative oversight of the program.

Respectfully submitted,
Malcolm J. Broussard
Executive Director